At the news
? NEUTRALIMPACT 4/10 PRESS-RELEASE filed Jun 9, 2026 at 07:01 ET
Invivyd dosed first participants in the LIBERTY Phase 3 trial evaluating VYD2311 (mAb) vs. mRNA COVID-19 vaccine, with topline data expected Q3 2026 alongside pivotal DECLARATION trial results. This is an early-stage clinical milestone with no efficacy or safety data yet, a routine pipeline update for a pre-revenue biotech.
- First participants dosed in LIBERTY Phase 3 trial (N≈210) comparing VYD2311 alone, mRNA vaccine alone, and co-administration.
- Topline data expected Q3 2026, concurrent with pivotal DECLARATION trial data.
- Primary endpoints are safety/tolerability through Day 6 (TEAEs, injection site reactions, systemic symptoms).
- LIBERTY is part of the broader REVOLUTION program aiming to position VYD2311 as a preferred COVID-19 prevention option over mRNA vaccines.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access